The Senate has a drug pricing bill. Now what?

We’ve had about 36 hours to pick apart the Senate Finance Committee’s drug pricing bill, and we have some questions.

As STAT’s Nicholas Florko points out, it remains unclear how much the proposal would actually help patients, how much it would actually harm drug companies, and whether it has a chance of becoming a law.

The first hurdle arrives later this morning, when the bill goes through markup, where it could end up laden with amendments. And then would come a floor vote, followed by House consideration and, eventually, the pen of President Trump.

Read more.